Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

  Number of patients (n = 48) (%)
Age   
 Median 76  
 Min-Max 70–86  
Sex   
 Male 24 50.0
 Female 24 50.0
Performance status (WHO)   
 0 11 22.9
 1 33 68.8
 2 4 8.3
Previous Treatment   
 Surgery 36 75.0
 Adjuvant chemotherapy 9 18.8
 Adjuvant radiotherapy 4 8.3
Disease Sites   
 Lymph nodes 15 31.3
 Liver 36 75.0
 Lung 17 35.4
 Other 11 23
Number of Metastatic Sites   
 1 22 45.8
 2 14 29.2
 3 10 20.8
 4 1 2.1
CGA (n = 48)   
 Fit 25 52.0
 Vulnerable 23 48.0
GDS (n = 30)   
 ≤5 22 73.3
 >5 8 26.7
 Median 4  
 Range 1–12  
MMSE (n = 32)   
 <24 4 12.5
 ≥24 28 27.5
 Median 27  
 Range 3–30  
IADL (n = 37)   
 <7 10 73.3
 7–8 27 26.7
 Median 8.0  
 Range 3–8  
Charlson Comorbidity Index   
 Median 1  
 Range 0–2  
Body Mass Index   
 Median 27.75  
 Range 18.0–35.0  
Haemoglobin (gr/dL)   
 Median 11.8  
 Range 9.7–16.4  
Albumin (gr/dL)   
 Median 3.9  
 Range 2.6–4.8  
Medications   
 Median 1  
 Range 0–4